Cystic Fibrosis
Conditions
Keywords
Endothelial Function, Maximal Exercise Capacity, Flow Mediated Dilation, Antioxidant, FEV1
Brief summary
Cystic fibrosis has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections. However, the physiological mechanisms for this reduced exercise capacity are unknown. The investigators recently published the first evidence of systemic vascular dysfunction in patients with CF. Therefore, it is reasonable to suspect that the blood vessels are involved with exercise intolerance in CF. This study will look at how and if oxidative stress contributes to both artery dysfunction and exercise intolerance in CF.
Detailed description
Cystic Fibrosis (CF) is the most common fatal genetic disease in North America. The most disturbing aspect of CF is the associated premature death, most often due to respiratory complications. Clinical manifestations of CF include not only lung dysfunction, but many other systemic consequences as well. Systemic oxidative stress and exercise intolerance are established phenotypes in patients with CF. Additionally, for the first time the investigators have recently published the presence of systemic endothelial dysfunction in a cohort of young patients with CF who exhibited normal oxygen saturation and spirometric function. Exercise intolerance, the limitation of the ability to perform exercise at the expected level, has been shown to predict mortality in patients with CF independent of lung function. Exercise capacity (VO2 peak), an objective measurement of exercise tolerance, drops approximately 5-8% per year in patients with CF. This excessive decay in exercise capacity not only leads to more pulmonary infections and deterioration of lung function, it represents a 5-8 fold decline compared to healthy sedentary adults. Preventing the excessive annual reduction in exercise capacity is essential to increasing the quality of life and longevity of patients with CF. However, a critical barrier to improving exercise capacity in CF is the investigators lack of knowledge regarding the different physiological mechanisms that contribute to exercise intolerance. It is important to emphasize that decreases in lung function (FEV1) do not always contribute to reductions in VO2 peak. Furthermore, less than 2% of patients who have an FEV1 greater than 50% predicted will have a significant drop in hemoglobin oxygen saturation (SpO2) during maximal exercise. These data suggest that mechanisms other than lung function induced hypoxemia may be contributing to exercise intolerance in patients with CF.
Interventions
DIETARY_SUPPLEMENTAcute Antioxidant
Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
DIETARY_SUPPLEMENTChronic Antioxidant
Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
OTHERPlacebo
Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
Sponsors
Augusta University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
7 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Diagnosis of CF and healthy controls * Men and women (\> 18 yrs. old) * Boys and girls (7-17 yrs. old) * FEV1 percent predicted \> 30% * Patients with or without CF related diabetes * Resting oxygen saturation (room air) \>90% * Traditional CF-treatment medications * Ability to perform reliable/reproducible PFTs * Clinically stable for 2 weeks (no exacerbations or need for antibiotic treatment within 2 weeks of testing or major change in medical status) * Pancreatic sufficient and pancreatic insufficient patients
Exclusion criteria
* Children 6 yrs. old and younger * FEV1 percent predicted \< 30% * Resting oxygen saturation (room air) \< 90% * Clinical diagnosis of heart disease, PAH * Febrile illness within two weeks of visit * Currently smoking, pregnant, or nursing * Individuals on vaso-active medications (i.e. nitrates, beta blockers, ACE inhibitors, etc.) * Patients with B. cepacia (only \ 3% of our CF center patient population) * Treatment for pulmonary exacerbation within 4 weeks of a study visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acute Change in Flow mediated dilation | Change from baseline (2 hours) | Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment |
| Chronic Change in Flow mediated dilation | Baseline, week 4, week 8, and week 12 | Flow-Mediated Dilation will be determined at baseline, week 4, week 8 and week 12. |
| Acute Change in exercise capacity (VO2 peak) | Baseline and 2 hours following acute antioxidant treatment | Subjects will perform a baseline maximal exercise capacity test and on a separate visit perform a maximal exercise capacity test 2 hours following acute antioxidant treatment |
| Chronic Change in exercise capacity (VO2 peak) | Baseline, week 4, week 8, and week 12 | Subjects will perform a maximal exercise capacity test at baseline, week 4, week 8, and week 12. |
Countries
United States
Outcome results
None listed